Edition:
United States

Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

201.41USD
22 Sep 2017
Change (% chg)

$1.17 (+0.58%)
Prev Close
$200.24
Open
$199.69
Day's High
$201.94
Day's Low
$199.69
Volume
986,743
Avg. Vol
937,371
52-wk High
$214.34
52-wk Low
$119.37

Select another date:

Thu, Sep 7 2017

BRIEF-Illumina files new patent infringement suit against Premaitha Health Plc

* Illumina Inc - ‍filed new patent infringement suit against Premaitha Health Plc in High Court of Justice, Chancery Division, Patents Court in UK Source text for Eikon: Further company coverage:

Illumina shares sparkle on strong demand for new gene tech

Shares of Illumina Inc surged nearly 14 percent on Wednesday, a day after the company raised its 2017 revenue forecast on strong demand for its new gene-sequencing technology.

CORRECTED-UPDATE 1-Illumina shares sparkle on strong demand for new gene tech

Aug 2 Shares of Illumina Inc surged nearly 14 percent on Wednesday, a day after the company raised its 2017 revenue forecast on strong demand for its new gene-sequencing technology.

Illumina shares sparkle on demand for new gene tech

Aug 2 Shares of Illumina Inc surged nearly 12 percent on Wednesday, a day after the company raised its full-year revenue forecast on higher-than-expected demand for its new gene-sequencing technology.

BRIEF-Illumina Q2 earnings per share $0.87

* Illumina reports strong financial results for second quarter of fiscal year 2017

Illumina notches win in prenatal testing patent fight

A federal appeals court on Tuesday revived a patent on fetal diagnostic testing that Illumina Inc has accused rival Sequenom Inc of infringing.

BRIEF-Inno-Gene says units reach agreement with Illumina over patent dispute

* SAID ON FRIDAY THAT ITS UNITS, CENTRUM BADAN DNA SP. Z O.O AND MEDGENETIX SP. Z O.O., REACHED SETTLEMENT WITH THE COMPANY ILLUMINA INC. CONCERNING VIOLATION OF INTELLECTUAL PROPERTY OF ITS PATENT

BRIEF-HTG Molecular amends, restates IVD test development, component supply agreement with Illumina

* Amended and restated its IVD test development and component supply agreement with Illumina

BRIEF-Illumina reports Q1 GAAP earnings per share $2.52

* Illumina reports financial results for first quarter of fiscal year 2017

Illumina, Cornell drop gene sequencing patent dispute

Cornell University and biotechnology company Illumina Inc have dropped a lengthy patent dispute over gene-sequencing technology, citing a "settlement process."

Select another date: